Singapore — The Covid-19 vaccine created by a pharmaceutical corporation, Pfizer and their German partner BioNTech has delivered their first batch of Covid-19 vaccine to Singapore.
Carried by the Singapore Airlines (SIA) Boeing 747-400 freighter, SQ7979, the vaccine came all the way from Brussels, Belgium to the Changi International Airport in Singapore. This is the first Pfizer vaccine shipment to an Asian country.
The Pfizer vaccine brought to Singapore at minus 70 degrees was specially stored in increased quantities of dry ice and it was loaded into a refrigerated truck once the flight landed for it to be transported into an external storage facility in the country.
Transport Minister of Singapore, Ong Ye Kung and the Director-general of the Civil Aviation Authority of Singapore, Mr Kevin Shum were present at the airport to receive the Covid-19 vaccine.
We are ready to do this and a lot of preparation work has gone into making this as smooth as possible.
Transport Minister Mr. Ong said.
The Pfizer Covid-19 vaccine is the first ever Covid-19 vaccine to be approved by the Health Sciences Authority in Singapore and by the US Food and Drug Administration.
Pfizer and their German partner BioNTech claimed that the Covid-19 vaccine they have made has proven to be 95% effective. The latest data revealed by these companies showed that their vaccine has overall proven to be 95% effective and 94% effective for the volunteers who were over the age of 65 – the individuals who have a weaker immune system compared to youngsters and are at the most risk from the virus.
This is a huge success for these companies as most of the vaccines that were made have proven to be considerably less effective among older people. This is why, several large countries including the United Kingdom and the United States have already started their first mass inoculation program using the Pfizer Covid-19 vaccine.
Along with this vaccine, another vaccine from a biotech company named Moderna had also revealed that they had received an effective result from their latest trial. According to Moderna, the early analysis of their Phase 3 trial suggested its vaccine was 94.5 percent effective. Their vaccine has also been approved by US FDA.
